RespiCellTM: An Innovative Dissolution Apparatus for Inhaled Products
Open Access
- 23 September 2021
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (10) , 1541
Abstract
To overcome some of the shortfalls of the types of dissolution testing currently used for pulmonary products, a new custom-built dissolution apparatus has been developed. For inhalation products, the main in vitro characterisation required by pharmacopoeias is the deposition of the active pharmaceutical ingredient in an impactor to estimate the dose delivered to the target site, i.e., the lung. Hence, the collection of the respirable dose (<5 µm) also appears to be an essential requirement for the study of the dissolution rate of particles, because it results as being a relevant parameter for the pharmacological action of the powder. In this sense, dissolution studies could become a complementary test to the routine testing of inhaled formulation delivered dose and aerodynamic performance, providing a set of data significant for product quality, efficacy and/or equivalence. In order to achieve the above-mentioned objectives, an innovative dissolution apparatus (RespiCell™) suitable for the dissolution of the respirable fraction of API deposited on the filter of a fast screening impactor (FSI) (but also of the entire formulation if desirable) was designed at the University of Parma and tested. The purpose of the present work was to use the RespiCell dissolution apparatus to compare and discriminate the dissolution behaviour after aerosolisation of various APIs characterised by different physico-chemical properties (hydrophilic/lipophilic) and formulation strategies (excipients, mixing technology).Keywords
This publication has 25 references indexed in Scilit:
- Dissolution Testing of Powders for Inhalation: Influence of Particle Deposition and Modeling of Dissolution ProfilesPharmaceutical Research, 2014
- Differences in physical chemistry and dissolution rate of solid particle aerosols from solution pressurised inhalersInternational Journal of Pharmaceutics, 2014
- Challenges with Developing In Vitro Dissolution Tests for Orally Inhaled Products (OIPs)AAPS PharmSciTech, 2012
- Drug Solubility: Importance and Enhancement TechniquesISRN Pharmaceutics, 2012
- Dissolution Techniques for In Vitro Testing of Dry Powders for InhalationPharmaceutical Research, 2012
- Critical Characteristics for Corticosteroid Solution Metered Dose Inhaler BioequivalenceMolecular Pharmaceutics, 2012
- Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilization on pharmacokinetic propertiesDrug Development and Industrial Pharmacy, 2010
- Development of a standardized dissolution test method for inhaled pharmaceutical formulationsInternational Journal of Pharmaceutics, 2009
- Manufacture, Characterization, and Pharmacodynamic Evaluation of Engineered Ipratropium Bromide ParticlesPharmaceutical Development and Technology, 2006
- Modeling and comparison of dissolution profilesEuropean Journal of Pharmaceutical Sciences, 2001